CASI Pharmaceuticals 的空头股数在 9 月份下跌了 9.4%，有 146,500 股被卖空。 CASI Pharmaceuticals' short interest declined 9.4% in September, with 146,500 shares shorted.

CASI Pharmaceuticals 9 月份的空头股数下跌了 9.4%，卖空了 146,500 股，低于 9 月 15 日的 161,700 股。 CASI Pharmaceuticals saw a 9.4% decline in short interest in September, with 146,500 shares shorted, down from 161,700 on September 15. 这占公司股份的3.4%,日对日比率为4.3天。 This represents 3.4% of the company’s shares, with a days-to-cover ratio of 4.3 days. 该公司报告季度损失0.52 EPS,超过估计。 The company reported a quarterly loss of $0.52 EPS, surpassing estimates. CASI侧重于发展治疗方法,包括治疗多种间皮瘤的EVOMELA。 CASI focuses on developing therapeutics, including EVOMELA for treating multiple myeloma.